Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243033 · ClinicalTrials.gov registry record
Phase II Laser Focal Therapy of Prostate Cancer
A clinical trial of Prostate Cancer, sponsored by HALO Diagnostics.
- Active
- Registry status
- 1,000
- Enrollment target
- 1
- Study location
NCT02243033 is a study of Prostate Cancer that is active but no longer recruiting, run by HALO Diagnostics. The registered enrollment target is 1,000 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher). The trial reports 1 study location across 1 state.
The verdict
NCT02243033, a study of Prostate Cancer, is active but no longer recruiting, sponsored by HALO Diagnostics.
- ACTIVE NOT RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Target recruitment: 1000 subjects. The purpose of this research study is to continue to investigate the safety and effectiveness of using MR (magnetic resonance) guided laser focal therapy for prostate cancer and to evaluate oncologic control over 20 years. We hypothesize that laser focal therapy can be used to achieve oncologic control in carefully selected patients. MR uses large magnets to produce pictures of areas/organs inside the body. The laser uses light to heat a target area to try to destroy cancerous cells. The laser system that will be used is called the Visualase® Thermal Therapy System. This system has been used for the treatment of brain, bone (spine), thyroid, and liver cancers. However; this study is the first time this system has been studied for use in the treatment of prostate cancer with a trans-rectal approach. MR-guided biopsies and laser applicator placement will be performed using the Invivo DynaTRIM trans-rectal biopsy guidance system. This system is cleared (approved) by the U.S. Food and Drug Administration (FDA) for such uses.
Conditions Studied
Interventions
- DEVICE MR-guided laser focal therapy
Study Locations (1)
California
- Desert Medical Imaging - Indian Wells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2016-05 |
| Est. Completion | 2036-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02243033
The ClinicalTrials.gov registry entry for NCT02243033 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (65% higher). The listed sponsor is HALO Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which MR-guided laser focal therapy is the first listed.
NCT02243033 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02243033 about?
NCT02243033 is a clinical study titled "Phase II Laser Focal Therapy of Prostate Cancer". Target recruitment: 1000 subjects. The purpose of this research study is to continue to investigate the safety and effectiveness of using MR (magnetic resonance) guided laser focal therapy for prostate cancer and to evaluate oncologic control over 20 years. We hypothesize that laser focal therapy ca...
What is the current status of trial NCT02243033?
This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2016-05. Estimated completion is 2036-11.
What conditions does trial NCT02243033 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT02243033?
The interventions under investigation include: MR-guided laser focal therapy (DEVICE).
Who is sponsoring clinical trial NCT02243033?
This trial is sponsored by HALO Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02243033 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.